Targeting the PI3K/AKT/mTOR pathway in prostate cancer development and progression

June 10, 2016

The research article - Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy, by Dr Claudio Festuccia (University of L'Aquila, Italy) and published in Clinical Cancer Drugs, volume 3, issue 1 - discusses experimental and clinical data on the pharmacological inhibition of the Akt/mTOR pathways. These pathways play a key role in the modulation of cellular proliferation, tumor growth and survival through phosphorylation of different downstream molecules. Prostate tumor growth and progression is negatively regulated by Phosphatase and tensin homolog (PTEN) which is genetically and/or functionally silenced in this neoplasia. The aim of the presentation was to analyze the synthesis and functional characterization of different compounds inhibiting phospatidylinositol-4,5-bisphosphate-3-kinase (PI3K), Akt and mTOR activities as well as the feasibility of these inhibitors functioning alone or in combination with standard therapies in aggressive castration resistant prostate cancers (CRPC), a disease stage characterized from high percentage of patients with bone metastases. Conventional treatment for this disease stage requires, indeed, a multidisciplinary approach (medical therapy, surgery, and radiation), but is primarily palliative. Pharmacological resistance is commonly observed. Activation of PI3K/Akt/mTOR pathways plays a significant role in therapy. The blockade of this pathway may be necessary to increase standard therapies. "Several preclinical data support the rationale to advance the use of pharmacological inhibitors of PI3k/Akt/mTOR into clinical trials in CRPC as performed for several other solid tumors" remarked Dr. Festuccia.
Author(s): Festuccia Claudio.

Affiliation: Department of Clinical and Applied Sciences and Biotechnologies, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy

This article is open access and can be downloaded from Bentham Science Publishers' webpage here:

Bentham Science Publishers

Related Tumor Growth Articles from Brightsurf:

New insights into colorectal cancer: Growth factor R-spondin suppresses tumor growth
R-spondin, which enhances the growth of healthy cells in the gut, suppresses the growth of intestinal adenoma cells, thus reducing the formation of intestinal tumors.

Finding a way to STING tumor growth
The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule.

Flipping a metabolic switch to slow tumor growth
The enzyme serine palmitoyl-transferase can be used as a metabolically responsive ''switch'' that decreases tumor growth, according to a new study by a team of San Diego scientists, who published their findings Aug.

Researchers determine how a specific protein regulates tumor growth
Immune checkpoints are surface proteins that cancer cells use to evade immune response.

Fibroblasts involved in healing spur tumor growth in cancer
The connective tissue cells known as fibroblasts are vitally important for our recovery from injury.

Glutamine-blocking drug slows tumor growth and strengthens anti-tumor response
A compound developed by Johns Hopkins researchers that blocks glutamine metabolism can slow tumor growth, alter the tumor microenvironment and promote the production of durable and highly active anti-tumor T cells.

Neurons promote growth of brain tumor cells
In a current paper published in the journal 'Nature', Heidelberg-based researchers and physicians describe how neurons in the brain establish contact with aggressive glioblastomas and thus promote tumor growth / New tumor activation mechanism provides starting points for clinical trials.

Hole-forming protein may suppress tumor growth
A gene called gasdermin E, which is downregulated in many cancers, aids cells in dying in an unexpected way, and may also suppress tumor growth.

New formula better predicts speed of tumor growth in 12 cancers
University at Buffalo researchers have developed a new method to more accurately predict tumor growth rates, a crucial statistic used to schedule screenings and set dosing regimens in cancer treatment.

Enlarged prostate could actually be stopping tumor growth, simulations show
Computer simulations show for the first time that when a patient has history of an enlarged prostate, tumors in the prostate barely grow at all.

Read More: Tumor Growth News and Tumor Growth Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to